Intracoronary Administration of Glucocorticoids as a Treatment Method for No-Glucocorticoid Treatment for No-Reflow in STEMI

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (446 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-06-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellmyocardialinjurytherapyimprove
  Phrases that lowered it: singleagedtrial is40 yearsapplied
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Minimum age: 40 (lowers risk) · Who can join
• Has a data monitoring committee: not given (lowers risk) · Design
• Blinding: single (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 15.8% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports before start: 91861 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 15770 (lowers risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Responsible party: sponsor (raises risk) · Design
• Drug's FAERS reports marked serious: 88.0% (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction NCT00590070 · started 2008 · scored riskier than 23% of active trials completed
• Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction NCT05462730 · started 2022 · scored riskier than 36% of active trials completed
• Oral Nicorandil for Prevention of No Reflow Phenomenon in Anterior STEMI Patients Undergoing PPCI NCT07138508 · started 2024 · scored riskier than 22% of active trials completed
• Concomitant Milrinone and Esmolol Treatment in Patients with Acute Myocardial Infarction NCT02098629 · started 2015 · scored riskier than 68% of active trials completed
• REperfusion Facilitated by LOcal Adjunctive Therapy in ST-elevation Myocardial Infarction NCT01747174 · started 2011 · scored riskier than 48% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.